How large should a phase II trial of a new drug be? - PubMed (original) (raw)
Review
. 1987 Nov;71(11):1079-85.
Affiliations
- PMID: 3315196
Review
How large should a phase II trial of a new drug be?
R Simon. Cancer Treat Rep. 1987 Nov.
Abstract
A number of statistical designs for phase II trials have been published. These designs are critically reviewed. A new design is also introduced. Data are presented on the response rates observed for new chemotherapeutic agents introduced by the National Cancer Institute since 1975. Based upon this material, it is recommended that two-stage designs with a target sample size of 35-50 patients and substantial probability of early termination are usually appropriate. It is also recommended that for active drugs, two to three such trials are necessary to estimate the response rate with reasonable precision. Precise estimation of phase II response rates is not always important, however. For very rare diseases or situations where several dose levels of a biologic are to be evaluated, selection designs may be most appropriate. Such designs are described. Tables are presented to facilitate the design of new agent phase II clinical trials.
Similar articles
- Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K, Shan M. Chen K, et al. Contemp Clin Trials. 2008 Jan;29(1):32-41. doi: 10.1016/j.cct.2007.04.008. Epub 2007 May 6. Contemp Clin Trials. 2008. PMID: 17544337 - Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH, Eisenhauer EA. El-Maraghi RH, et al. J Clin Oncol. 2008 Mar 10;26(8):1346-54. doi: 10.1200/JCO.2007.13.5913. Epub 2008 Feb 19. J Clin Oncol. 2008. PMID: 18285606 Review. - Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
Taylor JM, Braun TM, Li Z. Taylor JM, et al. Clin Trials. 2006;3(4):335-48. doi: 10.1177/1740774506070654. Clin Trials. 2006. PMID: 17060208 - Therapeutic response in phase I trials of antineoplastic agents.
Estey E, Hoth D, Simon R, Marsoni S, Leyland-Jones B, Wittes R. Estey E, et al. Cancer Treat Rep. 1986 Sep;70(9):1105-15. Cancer Treat Rep. 1986. PMID: 3527410 Clinical Trial. - Improving the design of phase II trials of cytostatic anticancer agents.
Stone A, Wheeler C, Barge A. Stone A, et al. Contemp Clin Trials. 2007 Feb;28(2):138-45. doi: 10.1016/j.cct.2006.05.009. Epub 2006 Jul 14. Contemp Clin Trials. 2007. PMID: 16843736 Review.
Cited by
- A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy.
Dowell JE, Johnson DH, Rogers JS, Shyr Y, McCullough N, Krozely P, DeVore RF. Dowell JE, et al. Invest New Drugs. 2001;19(1):85-8. doi: 10.1023/a:1006433528750. Invest New Drugs. 2001. PMID: 11291837 Clinical Trial. - Results of regional chemotherapy using the aortic stop-flow technique in advanced pancreatic carcinoma.
Meyer F, Gebauer T, Grote R, Martens-Lobenhoffer J, Ridwelski K, Lippert H. Meyer F, et al. Surg Today. 2006;36(2):155-61. doi: 10.1007/s00595-005-3119-z. Surg Today. 2006. PMID: 16440163 - The efficacy of paclitaxel and cisplatin combination chemotherapy for the treatment of metastatic or recurrent gastric cancer: a multicenter phase II study.
Shin SJ, Chun SH, Kim KO, Kim MK, Lee KH, Hyun MS, Bae SH, Ryoo HM, Do YR, Kwon KY, Song HS. Shin SJ, et al. Korean J Intern Med. 2005 Jun;20(2):135-40. doi: 10.3904/kjim.2005.20.2.135. Korean J Intern Med. 2005. PMID: 16134768 Free PMC article. Clinical Trial. - A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK. Kang HJ, et al. Br J Cancer. 2008 Jan 29;98(2):316-22. doi: 10.1038/sj.bjc.6604186. Epub 2008 Jan 22. Br J Cancer. 2008. PMID: 18219288 Free PMC article. Clinical Trial. - Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
Cho H, Ryu MH, Kim KP, Ryoo BY, Park SR, Kim BS, Lee IS, Kim HS, Yoo MW, Yook JH, Oh ST, Kim BS, Kang YK. Cho H, et al. Gastric Cancer. 2017 Nov;20(6):970-977. doi: 10.1007/s10120-017-0710-0. Epub 2017 Mar 16. Gastric Cancer. 2017. PMID: 28303362 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources